EP
KYMR icon

Edgestream Partners’s Kymera Therapeutics KYMR Stock Holding History

Edgestream Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,963
Closed -$386K – 1002
2025
Q4 		$386K Buy
+4,963
New +$335K 0.01% 851

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Edgestream Partners's KYMR Position: Q1 2026 in Review

Edgestream Partners sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 4,963 shares — an estimated $386K sold.

Edgestream Partners first reported a position in KYMR in Q4 2025 and held it in 1 quarter. The position peaked at $386K in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Edgestream Partners reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Edgestream Partners sold 4,963 Kymera Therapeutics shares in Q1 2026, an estimated $386K.
  • Edgestream Partners first reported a position in Kymera Therapeutics in Q4 2025 and held it in 1 quarter.
  • Edgestream Partners's Kymera Therapeutics position peaked at $386K in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Edgestream Partners's 13F filing for Q1 2026, filed 18 May 2026.